Shots:   

• The CHMP has recommended Gohibic (under exceptional circumstances) to treat SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) adults on systemic corticosteroids (SoC) & IMV (with/without ECMO), with the decision anticipated within 67days (Q1’24) 

• Opinion was backed by P-III (PANAMO) study of Gohibic vs PBO among invasively mechanically ventilated COVID-19 patients in ICU, showing improvement in survival with a 23.9% relative reduction in 28-day all-cause mortality. Data was published in The Lancet Respiratory Medicine  

• The company is seeking commercial distribution partnerships in the EU for Gohibic (mAb targeting human complement factor C5a) 

Ref: Inflarx | Image: Inflarx

Related News:- InflaRx Receives the US FDA’s EUA for Gohibic (vilobelimab) to Treat COVID-19

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com